APA (7th ed.) Citation

Stav Brown, Audree B. Tadros, Giacomo Montagna, Tajah Bell, Fionnuala Crowley, Fionnuala Crowley, . . . Joseph H. Dayan. (2024). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND). Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Stav Brown, Audree B. Tadros, Giacomo Montagna, Tajah Bell, Fionnuala Crowley, Fionnuala Crowley, Emily J. Gallagher, Joseph H. Dayan, and Joseph H. Dayan. Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) May Reduce the Risk of Developing Cancer-related Lymphedema Following Axillary Lymph Node Dissection (ALND). Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Stav Brown, et al. Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) May Reduce the Risk of Developing Cancer-related Lymphedema Following Axillary Lymph Node Dissection (ALND). Frontiers Media S.A., 2024.